Skip to main contentAI and Advanced
/
RUBICON · NSEBSE SENSEX74,294.96-0.03%BSE |
NIFTY 5023,346.4+0.33%NSE |
NIFTY BANK56,358.7+0.54%NSE |
NIFTY IT28,854.55-1.03%NSE |
NIFTY AUTO27,129-0.11%NSE |
NIFTY FMCG45,466.8-0.23%NSE |
NIFTY PHARMA26,710.1+0.49%NSE |
NIFTY 50022,840.55+0.82%NSE |
RU
NSE · Equity shares · Biotechnology & Drugs-33.30 · -1.87%
Rubicon Research RUBICON
NSE:INR 1,745
BSE:INR 1,747.4
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for RUBICON
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 1,778.3
Day rangeINR 1,766.7 — INR 1,834.9
52-week rangeINR 570.75 — INR 1,899
Volume1.82 L
Market cap25,661.62
P/E50.14
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)1,753.96
Net Income (INR Cr)246.73
P/E Ratio50.14
Book Value74.14
EPS15.39
Price/BV23.54Computed
Research path: Interpret Rubicon Research's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
RUBICONRubicon Research1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 2,326.71 | 1,451.43 | 1,109.49 |
| Accumulated Depreciation Total | -177.72 | -139.09 | -116.5 |
| Other Liabilities Total | 19.32 | 43.38 | 37.35 |
| Accrued Expenses | 33.56 | Not available | Not available |
| Long Term Debt | 143.02 | 64.47 | 92.6 |
| Common Stock Total | 16.51 | 15.41 | 15.21 |
| Other Equity Total | -10.66 | -13.65 | -8.9 |
| Other Current Assets Total | 12.63 | 25.12 | 36.93 |
| Prepaid Expenses | 40.24 | 54.6 | 42.23 |
| Total Assets | 2,326.71 | 1,451.43 | 1,109.49 |
| Current Portof LT Debt/Capital Leases | 60.6 | 46.45 | 45.66 |
| Additional Paid-In Capital | 745.92 | 259.86 | 237.85 |
| Cash | 185.65 | 0.02 | 0.04 |
| Total Equity | 1,288.82 | 540.99 | 385 |
| Long Term Investments | 26.59 | 7.43 | 7.96 |
| Retained Earnings(Accumulated Deficit) | 537.06 | 279.36 | 140.85 |
| Total Common Shares Outstanding | 16.51 | 15.44 | 15.44 |
| Property/Plant/Equipment Total-Gross | 685.52 | 415.11 | 373.33 |
| Tangible Book Valueper Share Common Eq | 74.14 | 31.29 | 21.04 |
| Goodwill Net | 53.9 | 47.61 | 51.33 |
| Total Liabilities | 1,037.89 | 910.45 | 724.49 |
| Total Debt | 311.01 | 417.61 | 424.52 |
| Short Term Investments | 150.55 | 22.01 | 23.66 |
| Cashand Short Term Investments | 336.21 | 138.25 | 82.05 |
| Total Receivables Net | 546.1 | 323.79 | 301.47 |
| Notes Payable/Short Term Debt | 67.7 | 290.12 | 264.22 |
| Accounts Receivable-Trade Net | 508.74 | 323.79 | 301.47 |
| Property/Plant/Equipment Total-Net | 507.8 | 276.02 | 256.83 |
| Minority Interest | 0 | Not available | Not available |
| Total Current Liabilities | 835.87 | 786.03 | 572.5 |
| Total Inventory | 746.63 | 521.61 | 300.49 |
| Accounts Payable | 377.46 | 239.12 | 176.73 |
| Other Currentliabilities Total | 296.54 | 210.35 | 85.89 |
| Total Long Term Debt | 182.7 | 81.04 | 114.64 |
| Intangibles Net | 10.85 | 10.19 | 8.74 |
| Other Long Term Assets Total | 27.6 | 37.29 | 16.69 |
| Note Receivable-Long Term | 18.16 | 9.53 | 4.76 |
| Total Current Assets | 1,681.81 | 1,063.37 | 763.17 |
| Capital Lease Obligations | 39.68 | 16.57 | 22.04 |
| Cash Equivalents | Not available | 116.21 | 58.35 |
| Deferred Income Tax | Not available | 0 | 0 |
Fundamentals
Valuation and ratios
Margins
Operating Margin 12m20.04
Net Profit Margin 12m14.07
Yield
Dividend Yield %0
Valuation
Price to Sale Ratio14.63
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk46.59
Analyst consensus
ConsensusStrong Buy
Consensus score1.00
Analyst opinions1
Strong Sell count0
Sell count0
Hold count0
Buy count0
Strong Buy count1
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 59.76%
- FII
- 7.52%
- MF
- 7.23%
- Other
- 25.49%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Rubicon Research fixes Aug 7 record date for ₹1.50 dividend - scanx.tradeMarket news · 20 Jul 2026, 7:04 pm
Rubicon Research fixes Aug 7 record date for ₹1.50 dividend scanx.trade
Nykaa Stock And 2 Fast Growth Picks With High Insider Ownership - simplywall.stMarket news · 17 Jul 2026, 3:08 am
Nykaa Stock And 2 Fast Growth Picks With High Insider Ownership simplywall.st
Rubicon Research IPO opens: Brokerage gives Subscribe rating; GMP jumps - MSNMarket news · 15 Jul 2026, 1:47 am
Rubicon Research IPO opens: Brokerage gives Subscribe rating; GMP jumps MSN
Rubicon Research - Concurrent Gainers: 10 stocks that gained for 5 days in a row - The Economic TimesMarket news · 11 Jul 2026, 12:30 pm
Rubicon Research - Concurrent Gainers: 10 stocks that gained for 5 days in a row The Economic Times
Rubicon Research - 10 microcap stocks rally up to 430% in CY26; 5 turn multibaggers: Here’s FII and MF exposure - The Economic TimesMarket news · 8 Jul 2026, 12:30 pm
Rubicon Research - 10 microcap stocks rally up to 430% in CY26; 5 turn multibaggers: Here’s FII and MF exposure The Economic Times
Rubicon Research receives two procedural observations after USFDA inspection - Business StandardMarket news · 6 Jul 2026, 12:30 pm
Rubicon Research receives two procedural observations after USFDA inspection Business Standard
Corporate actions
Events
- annual General MeetingAGM
- dividendRs.1.5000 per share(150%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- annual General MeetingPOM
- board MeetingsQuarterly Results
- annual General MeetingPOM
- board MeetingsQuarterly Results
Rusaka Markets Community
Discussion and sentiment for Rubicon Research
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Rubicon Research Ltd is an India-based pharmaceutical formulations company, which is focused on research and development, with a portfolio of specialty products and drug-device combination products targeting regulated markets, and particularly the United States. Its portfolio spans multiple dosage forms, including oral solids, oral liquids, nasal, and topical. Its technologies include RubiReten and RubiSRL. Its services include intellectual property evaluation and product design, formulation research development, analytical research development, technology transfer, dossier compilation and regulatory support, and clinical trials supplies. Its products are spread across many therapeutic areas, such as Analgesics/Pain Management, CVS, CNS, Hypokalemia, Skeletal Muscle Relaxants, NRT, Gastrointestinal, Metabolic, Immunosuppressant, and others. Others include Antipyretic, Hormonal Products, Diuretic, Antimuscarinics, Oral Rehydration Therapy, Over the Counter products, and Respiratory.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- RUBICON
- BSE Code
- 544578
Questions
Stock FAQ
What is the symbol and ISIN of Rubicon Research?
Rubicon Research has the symbol RUBICON and ISIN - INE506V01022.
What is the current price of Rubicon Research?
Rubicon Research is currently trading at INR 1,745.00.
What are the year high and year low of Rubicon Research?
Rubicon Research has a year high of INR 1,899.00 and a year low of INR 570.75.
What is the market capitalization of Rubicon Research?
Rubicon Research has a market capitalization of INR 25,661.62 crore.
What is the P/E ratio of Rubicon Research?
Rubicon Research has a P/E ratio of 50.14.
What is the dividend yield of Rubicon Research?
Rubicon Research has a dividend yield of 0.00%.
How is the financial performance of Rubicon Research based on revenue, net income, and EPS?
Rubicon Research has revenue of INR 1,753.96 crore, net income of INR 246.73 crore, and EPS of INR 15.99.
What is the book value of Rubicon Research?
Rubicon Research has a book value of INR 74.14.
What is the debt-to-equity ratio of Rubicon Research?
Rubicon Research has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Rubicon Research?
Rubicon Research has a price-to-book ratio of 23.54 and a price-to-sales ratio of 14.63.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.